Tagged with Clinical Trials,

UAE With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and a high regional prevalence of genetic diseases, it seems that the stage is set for the UAE to assume a…

China Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical trials are increasingly focusing on patient engagement and patient centricity.   In recent years, with the Chinese government’s vigorous support…

Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines.   Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…

Hong Kong Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research landscape. Strengthened by its experience in conducting COVID-19 vaccine trials, the global trends towards clinical research in Asia and more…

Hong Kong Fresh from the news that one of its AI-designed and discovered drug candidates has entered Phase II human clinical trials – the first time that such a project has made it to that development stage – Insilico Medicine’s Alex Zhavoronkov sat down with PharmaBoardroom to discuss a range of topics.…

Hong Kong Henry Yau is managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong Kong and CEO of the Centre’s mainland China arm. Yau explains how the clinical trials landscape has evolved in Hong Kong over the past five years, especially in relation to the COVID-19 pandemic. He…

Hong Kong MSD’s managing director for Hong Kong and Macau, Vincent Tong, came to lead the affiliate during the COVID-19 pandemic. He outlines the challenges and opportunities of a challenging time, discusses the leading position of the company’s cancer treatment Keytruda and his efforts as board member of the Hong Kong Association…

UAE Only a small percentage of global clinical research takes place in the Middle East and Africa region today. This means that full-service MEA-focused clinical research organisation PDC CRO has a wealth of untapped opportunities to develop, according to the company’s CEO Mohamed Mostafa. He outlines PDC’s important work on COVID-19…

Belgium With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more than 20 years there, Dr Isabelle Huyghe shares the workings of the PCRU, explains how study participants are recruited, and…

Belgium Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical trials. Pharma industry leaders and Belgian government officials weigh in on the factors threatening the country’s position as a clinical…

United Kingdom Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British government has announced a GBP 650 million “Life Sci for Growth” package along with some pro-innovation regulation and a review…

Belgium Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years, as well as an important R&D hub. Johan Heylen describes the continuing relevance of the country to the company, the…